About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Its lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. Hexokinase is an enzyme in the pathway that allows cancer cells to convert glucose to energy to fuel cancer cell growth.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CALA
- Previous Close: $8.95
- 50 Day Moving Average: $6.03
- 200 Day Moving Average: $3.84
- 52-Week Range: $20,737,000.00 - $2.20
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.82
- P/E Growth: -0.06
- Market Cap: $200.74B
- Outstanding Shares: 20,737,000
- Beta: 3.18
- Return on Equity: -58.24%
- Return on Assets: -54.26%
Companies Related to Calithera Biosciences:
- Current Ratio: 12.21%
- Quick Ratio: 12.21%
What is Calithera Biosciences' stock symbol?
Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."
Where is Calithera Biosciences' stock going? Where will Calithera Biosciences' stock price be in 2017?
5 brokerages have issued 12-month target prices for Calithera Biosciences' shares. Their predictions range from $5.00 to $12.00. On average, they anticipate Calithera Biosciences' stock price to reach $9.75 in the next twelve months.
When will Calithera Biosciences announce their earnings?
Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns Calithera Biosciences stock?
Calithera Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (1.86%) and Oxford Asset Management (0.24%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp Llc, Adage Capital Partners Gp, LL and Curtis Hecht.
Who bought Calithera Biosciences stock? Who is buying Calithera Biosciences stock?
Calithera Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management and FMR LLC. Company insiders that have bought Calithera Biosciences stock in the last two years include Adage Capital Partners Gp Llc and Adage Capital Partners Gp, LL.
How do I buy Calithera Biosciences stock?
Shares of Calithera Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Calithera Biosciences stock cost?
One share of Calithera Biosciences stock can currently be purchased for approximately $9.20.